Talnetant

Chemical compound

none

Identifiers

IUPAC name

3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide

CAS Number

174636-32-9^Y

PubChem CID

133090

IUPHAR/BPS

2124

ChemSpider

117450^N

UNII

CZ3T9T146K

ECHA InfoCard100.236.526

Chemical and physical dataFormulaC₂₅H₂₂N₂O₂Molar mass382.463 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O

InChI

InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)^N
Key:BIAVGWDGIJKWRM-UHFFFAOYSA-N^N

^NY (what is this?) (verify)

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.^[1]^[2]^[3]^[4]

References

^ "UPDATE 1-GlaxoSmithKline prunes new drug pipeline". Reuters. Oct 15, 2007.
^ Evangelista S (July 2005). "Talnetant GlaxoSmithKline". Current Opinion in Investigational Drugs. 6 (7): 717–21. PMID 16044668.
^ Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, et al. (September 2007). "Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans". Neurogastroenterology and Motility. 19 (9): 732–43. doi:10.1111/j.1365-2982.2007.00934.x. PMID 17727393. S2CID 11876042.
^ Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, et al. (June 2008). "In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia". Neuropsychopharmacology. 33 (7): 1642–52. doi:10.1038/sj.npp.1301549. PMID 17728699.